Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
批准号:
9255053
负责人:
Rajan P Adhikari
金额:
$29.49万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-02-15 至 2019-01-31
关键词:
AddressAdverse effectsAffinityAlpha CellAnimalsAnthrax VaccinesAnthrax diseaseAntibiotic TherapyAntibioticsAntibodiesAntigensAntitoxinsAwardBacillus (bacterium)Bacillus anthracisBacillus anthracis sporeBacteriaBacterial ToxinsBacteriophagesBindingBinding SitesBiological AssayBiological Response Modifier TherapyBioterrorismBlood CirculationCartoonsCatalytic DomainCell WallCellsCenters for Disease Control and Prevention (U.S.)Chimeric ProteinsClostridium difficileCodon NucleotidesCollaborationsComplexContractsDiseaseEnvironmentEnzymesEscherichia coliExposure toFc ReceptorFluorescenceFoodGenerationsGoalsGram-Positive BacteriaHumanImmuneIn VitroInfectionInflammationJournalsLaboratoriesLengthLettersLifeLinkMammalsMarylandMediatingMicroscopicMonoclonal AntibodiesMusN-terminalNatureOralOrganismPathogenesisPerformancePhagocytesPlayPolysaccharidesPowder dose formProbabilityProteinsPublic HealthPublishingRecommendationReporterReportingReproduction sporesResistanceRiskRoleRouteSafetySiteSkinSpecies SpecificitySpecificitySurfaceSurface Plasmon ResonanceTechnologyTestingTherapeuticTimeTissuesToxinUSSRVaccinesVirulenceWaterZoonosesaerosolizedanthrax lethal factoranthrax protective factorbactericidebasecostedema factorefficacy testingendolysingastrointestinalhuman monoclonal antibodiesimmunogenicityimprovedin vivokillingsmass casualtymembermouse modelneutralizing monoclonal antibodiesneutrophilnew technologynewsnovel strategiespathogenpreventprototypescaffoldscreeningsynergismweapons
中文摘要
项目摘要
革兰氏阳性细菌炭疽芽孢杆菌是潜在的生物武器化的非常有力的候选者,以及
据信实际上已被前苏联武器化。炭疽孢子很容易在
天然或在实验室中生产的,能抵抗恶劣条件,并能在
环境。微小的孢子可以制成粉末、喷雾剂、食物或水的形式。两种关键毒素
由保护性抗原(PA)与致死因子(LF)或水肿性因子(EF)结合而产生
炭疽杆菌毒力的关键作用。美国疾病控制与预防中心在可能暴露于
炭疽杆菌气雾化孢子由口服抗生素和以PA为基础的炭疽疫苗组成。
然而,在实践中,这些治疗方法不能充分解决细菌毒素的不良影响。
发布曝光后的照片。在这个R41提案中,我们打算开发一种新的方法来针对中和反
针对感染部位的毒素抗体。该方法利用细胞壁靶向结构域(CWT)
特性良好的噬菌体内毒素:PlyG、PlyL和PlyB,它们具有物种特异性和高亲和力
对炭疽芽胞杆菌细胞壁成分的影响。这些CWTs将与特定的抗毒素中和单抗融合
产生感染部位靶向抗毒素抗体(ISTAbs)的抗体。预计ISTAb将
在最需要它们的感染部位蓄积,并捕获和隔离毒素,从而
立即中和毒素的影响,防止它们释放到循环中。细菌毒素
然后,复合体有望被吞噬细胞清除。在这项提案中,我们将使用三种炭疽-PA中和
将单抗与高亲和力噬菌体内溶蛋白CWTS融合,产生ISTAb。在《目标1》中,我们将放映
获得来自10种噬菌体内毒素的最佳结合CWTs,包括来自PlyG、PlyL和PlyB的内毒素。我们会
根据体内和体外结合来表征它们。在目标2中,根据目标1的结果,我们将选择3个CWTS
通过将CWTS与三个高度中和的抗炭疽单抗融合而产生多达九个ISTAb
以抗体为支架,对其体外结合活性和毒素中和活性进行表征。在《目标3》中,我们将
根据稳定性、细菌细胞结合的特异性和亲和力进一步表征所选的ISTAb,以及
吞噬细胞杀伤试验中的表现。在目标4中,我们将在挑战前和
激发治疗后的小鼠模型,并探索ISTAbs的潜在免疫原性。
由于ISTAb技术提供了两个治疗优势:立即中和毒素
感染和吞噬细胞对吞噬细胞的杀伤,这些分子很可能会
与现有的抗生素协同作用。立即清除毒素、吞噬杀灭和
同时使用抗生素有望产生协同效应,并产生远远优于目前的治疗方法
疫苗加抗生素的标准。此外,这项技术还可以应用于各种其他细菌
毒素在致病机制中起关键作用的病原体。总体而言,这种方法在董事会中得到了应用
跨多种病原体的平台技术。
英文摘要
Project Summary
The Gram-positive bacterium Bacillus anthracis is a very strong candidate for potential bio- weaponization, and
believed to have actually been weaponized by the former Soviet Union. Anthrax spores are readily found in
nature or produced in the laboratory, are resistant to harsh conditions, and can survive for a long time in the
environment. The microscopic spores could be formulated in powder form, sprays, food, or water. Two key toxins
generated by combination of the protective antigen (PA) with either lethal factor (LF) or edema factor (EF) play
a critical role in B. anthracis virulence. Current CDC recommendations following potential exposure to
aerosolized B. anthracis spores consist of a combination of oral antibiotics and PA-based anthrax vaccine.
However, in practice, these treatments cannot adequately address the adverse effects of bacterial toxins
released post exposure. In this R41 proposal we intend to develop a novel approach to target neutralizing anti-
toxin antibodies specifically to the site of infection. The approach exploits the cell wall targeting domains (CWT)
of well characterized phage endolysins: PlyG, PlyL and PlyB which bind with species-specificity and high affinity
to cell wall components of B. anthracis. Theses CWTs will be fused to specific antitoxin neutralizing monoclonal
antibodies to generate Infection Site Targeted Antitoxin antibodies (ISTAbs). ISTAbs are expected to
accumulate at the site of infection where they are needed most, and capture and sequester the toxins, thus
immediately neutralizing the effects of the toxins and preventing their release into circulation. Bacterium-toxin
complex is then expected to be cleared by phagocytes. In this proposal, we will use three anthrax-PA neutralizing
monoclonal antibodies fused to high affinity phage endolysin CWTs to generate ISTAbs. In Aim 1 we will screen
for best binding CWTs from ten phage endolysins, including those from PlyG, PlyL, and PlyB. We will
characterize them based on in vivo and in vitro binding. In Aim 2, based on Aim 1 results, we will select 3 CWTs
for generating up to nine ISTAbs by fusing the CWTs with three highly neutralizing anti-Anthrax monoclonal
antibody as scaffold and characterize them for in vitro binding and toxin neutralizing activity. In Aim 3 we will
further characterize the selected ISTAbs based on stability; bacterial cell binding specificity and affinity, and
performance in opsonophagocytic killing assays. In Aim 4, we will perform efficacy testing in pre-challenge and
post challenge treatment mouse models and also explore potential immunogenicity of the ISTAbs.
Since ISTAb technology provides two therapeutic advantages: immediate toxin neutralization at the site of
infection and opsonophagocytic killing by phagocyte, there is a high probability that these molecules will
synergize with existing antibiotics. The combination of immediate toxin clearance, phagocytic killing, and
concurrent use of antibiotics is expected to create synergy and yield a treatment that is far superior to the current
standard of vaccine plus antibiotics. Furthermore, this technology can be applied to a variety of other bacterial
pathogens where toxins play a key role in pathogenesis. Overall, this approach has board application as a
platform technology across multiple pathogens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ISTAb- A novel therapy to target staphylococcal toxins at the site of infections
-
批准号:9890989
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2019
-
负责人:Rajan P Adhikari
-
依托单位:
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
-
批准号:10199998
-
项目类别:
-
资助金额:$66.33万
-
财政年份:2017
-
负责人:Rajan P Adhikari
-
依托单位:
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
-
批准号:9973142
-
项目类别:
-
资助金额:$98.53万
-
财政年份:2017
-
负责人:Rajan P Adhikari
-
依托单位:
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
-
批准号:10817474
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2017
-
负责人:Rajan P Adhikari
-
依托单位:
In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus
-
批准号:8645454
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2014
-
负责人:Rajan P Adhikari
-
依托单位:
A novel Structure Based Vaccine for staphylococcal alpha hemolysin
-
批准号:8465176
-
项目类别:
-
资助金额:$29.08万
-
财政年份:2012
-
负责人:Rajan P Adhikari
-
依托单位:
A novel Structure Based Vaccine for staphylococcal alpha hemolysin
-
批准号:8251485
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:Rajan P Adhikari
-
依托单位:
海外基金